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Guanmeng Wang: a heavy-chain-only CAR-T cell therapy elicits comparable antitumor response 
compared with canonical CAR-T cell 
(Under the direction of Gianpietro Dotti) 
 
Despite the encouraging antitumor efficacy of CAR-T cells in blood malignancies, the response 
of CAR-T cells in solid tumors is less pronounced. The undermined response is caused by characteristics 
of solid tumors such as tumor antigen heterogeneity and immunosuppressive tumor microenvironments. 
We developed a CAR construct that only includes heavy chain instead of the scFv. The small size of the 
heavy chain could break the size limit of the viral vector to overcome hypofunction of CAR-T cells in 
solid tumors by allowing additional transgenes into the CAR construct. Transduced T cells showed robust 
expansion, high expression of CAR and similar immunophenotypes compared with conventional scFv 
CAR-T cells.  Immunoblotting demonstrates comparable signaling of heavy-chain only CAR-T cells with 
scFv CAR-T cells. In vitro coculture showed potent cytotoxicity of heavy-chain-only CAR-T cells 
without off-target effect and significant release of proinflammatory cytokines. The murine model 
demonstrated strong antitumor response of heavy-chain-only CAR-T cells. 
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CHAPTER 1: INTRODUCTION 
1.1 Cancer Immunotherapy 
 
Immunotherapy utilizes human’s own immune system to cure diseases. Cancer immunotherapy, 
in particular, has gained much attention in recent years as it demonstrated promising tumor regressions in 
many forms of late stage cancers that cannot be cured by conventional chemotherapy and radiotherapy 
(Borghaei et al., 2009; Hodi et al., 2010; Kantoff et al., 2010). Cancer immunotherapies can be classified 
as active and passive immunotherapies: active immunotherapies activate endogenous immune system, 
while passive immunotherapies relay on transferring components of the immune systems to patients (Ito 
and E.Chang, 2013). Regardless of the type of immunotherapies, cancer cells can be recognized and 
killed by the patient’s own immune system which generally does not identify cancer cells. Monoclonal 
antibody (mAb) and adoptive cell transfer (ACT) therapy are the two major immunotherapies tested in 
clinical trials and some are approved by the Food and Drug Administration (FDA). 
1.2 Chimeric Antigen Receptor (CAR)-T cell Immunotherapy 
 
CAR-T cell immunotherapy belongs to the ACT therapy where T cells from the patients or 
healthy donors are genetically modified, cultured ex vivo and transfused back to the patients to treat 
cancer (Brentjens et al., 2014; Hollyman et al., 2009; Somerville et al., 2012; Vera et al., 2010). A CAR 
typically consists of an extracellular antigen-binding domain from a single-chain fragment variable(scFv) 
of antibodies, a transmembrane domain (CD8α), a costimulatory domain (CD28 or 4-1BB) and an 
intracellular domain (CD3ζ) (Geiger and Jyothi, 2001). Compared with traditional T cell receptors, CAR 
recognizes surface antigen in an MHC-independent manner. The first-generation CAR-T cells lack the 
costimulatory domain and causes insufficient antitumor effects. Therefore, most clinical trials up to date 
use second generation CAR-T cells in which one costimulatory domain and third-generation CAR-T cells   
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in which two costimulatory domains have been included and are in clinical studies (June et al., 2018). 
Most of the clinical success comes from the treatment of hematological malignancies. CD19 is a 
very effective target for B cell malignancies due its consistent and exclusive expression in B cell lineage 
(van Zelm et al., 2006). In clinical trials in acute lymphoblastic leukemia and lymphoma up to 90% of the 
patients achieved complete remission (Davila et al., 2014; Kochenderfer et al., 2015; Porter et al., 2015; 
Turtle et al., 2016). FDA approved two CD19.CAR-T cell therapies, Kymriah and Yescarta, in 2017 and 
2018 to treat B-cell acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (NHL). 
Based on these promising clinical results, multiple clinical studies are currently ongoing in several 
institutions. The following table summarizes active clinical trials of CAR-T cells at UNC. 
Target Antigen Disease Clinical Trials Identifier 
CD19 Acute Lymphoblastic 
Leukemia 
NCT03016377 
CD19 B Cell Lymphoma NCT03696784 
GD2 Neuroblastoma NCT03721068 
CD30 Non-Hodgkin Lymphoma NCT03602157 
CD138 Multiple Myeloma NCT03672318 
 
Table 1. Ongoing clinical trials of CAR-T immunotherapy at UNC Lineberger Comprehensive 
Center 
1.3 Limitation of CAR-T cells therapy for solid tumors 
 
Although promising clinical results are achieved on B-cell malignancies with CD19.CAR-T cells, 
moving beyond the CD19 target in solid tumors entails many challenges. Solid tumors do not express 
tumor-associated antigens (TAA) that are ideal for CAR-T cells in the case of blood malignancies. Most 
of the antigens expressed by solid tumors are also expressed at low levels in normal tissues. Furthermore, 
the heterogeneity of antigen expression in tumor cells of solid tumors, favors the possibility of tumor 
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escape due to lack or loss of antigen expression (Newick et al., 2017). Trafficking of the CAR-T cells into 
the solid tumors is also impaired due to the lack of chemokine and receptor mismatch between tumor cells 
and T cells, especially CXCR3hi CD8+ T cells (Harlin et al., 2009). The immunosuppressive tumor 
microenvironment (TME) of solid tumors creates both a physical and metabolic obstacle for CAR-T cells. 
The sinuous structure of tumor stroma, high pressure inhibits extravasation, low concentration of oxygen 
or hypoxia, and lack of nutrient like glucose all jeopardize T cell effector functions (Fischer et al., 2007; 
Hatfield et al., 2015).  The immunosuppressive TMEs also secrete cytokines such as TGFβ, IL-4 and 
soluble factors like prostaglandin E2(PGE2) which inhibit T cell proliferation and antitumor responses 
(Goodwin et al., 1977; Massagué, 2008). Lastly, the immunosuppressive immune cells residing in the 
TME such as regulatory T cells (Tregs), myeloid derived suppressor cells (MDSCs) and tumor-associated 
macrophages (TAMs) produce immunosuppressive cytokines, express immune checkpoints, and finally 
down-regulate T cell functions (Gabrilovich and Nagaraj, 2009; Sakaguchi et al., 2010). 
1.4 Safety issues of CAR-T cell therapy 
The safety concerns of CAR-T cell therapy arise from the unwanted immunological responses. 
When the TAA targeted by CAR-T cells is expressed on normal tissues, these tissues will be damaged, 
the cases of which are common in B-cell malignancies treated by CD19.CAR-T cell leading to significant 
B cell aplasia (Grupp et al., 2013; Kochenderfer et al., 2012; Kochenderfer et al., 2010). This side effect 
is also called “on-target/off-tumor” recognition. The most common and significant safety concern is 
cytokine release syndrome (CRS). Upon transfusion of CAR-T cells in patients, elevated level of 
proinflammatory cytokines are observed, which include interlukin-6(IL-6), interferon-γ(IFN-γ), 
interlukin-2(IL-2) and tumor necrosis factor (TNF) and other immune cells are activated by CRS and 
contributing further to CRS. Patients have symptoms including high fever, fatigue, malaise, nausea, 
hypertension, cardiac dysfunction and hepatic failure (Lee et al., 2014). The degree of CRS generally 
correlates with the tumor burden of the patients at the time of infusion with higher tumor burden 
indicating more severe CRS (Davila et al., 2014; Lee et al., 2015). Neurological toxicities are also 
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observed following CAR-T cell treatment with unknown mechanism. Known symptoms include 
headaches, confusion, hallucination, seizures, and dysmetria (Grupp et al., 2013; Kochenderfer et al., 
2012; Kochenderfer et al., 2010; Lee et al., 2014). It is speculated that elevated levels of cytokines are 
responsible for the toxicities, leading to increased permeability of central nervous system parenchyma 
(June et al., 2018). 
1.5 Objective 
 
Compared with traditional scFv CAR, a heavy-chain-only CAR offers a small size advantage, 
which allows to incorporate other transgenes into the construct, has limited immunogenicity and avoids 
the aggregation issue in scFv(Vu et al., 1997). In this work, a heavy-chain-only CAR construct was 
developed. The heavy-chain-only CAR-T cells achieve comparable antitumor response compared with 
traditional scFv CAR-T cells both in vitro and in vivo. This proof-of-concept experiment lays the 
foundation for further development of heavy-chain-only CAR-T cells to optimize CAR-T cell functions in 
solid tumors and manage CAR-T cell toxicities.
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CHAPTER 2: HEAVY-CHAIN-ONLY CAR-T CELL 
2.1 Materials and Methods 
 
CAR construction. Conventional PSMA.CAR (J591), heavy chain only PSMA.CAR (HuVh), 
conventional MSLN.CAR (scFv), heavy chain only MSLN.CAR(HuVh) were assembled with the CD8α 
hinge (H), transmembrane domain (TM), the CD28 costimulatory domain (CD28) and CD3ζ intercellular 
signaling domain and cloned into the SFG retroviral vector(Diaconu et al., 2017). A FLAG-tag was 
incorporated after both heavy chains to detect the expression of CARs by anti-FLAG Ab through flow 
cytometry. 
Cell lines. Tumor cell lines PC-3, C4-2(prostate cancer) and Aspc-1(pancreatic cancer) were 
purchased from ATCC. All tumor cell lines were cultured with RPMI-1640(Gibco) supplemented with 
10% FBS (Sigma), 2 mM GlutaMax (Gibco) and penicillin (100 units/mL) and streptomycin (100 µg/mL; 
Gibco). All cells were cultured at 37°C with 5% CO2. PC-3 cell line was transduced with retroviral vector 
encoding PSMA to make PC-3-PSMA and both PC-3-PSMA and Aspc-1 were transduced with retroviral 
vectors encoding Firefly- Luciferase-eGFP (FFluc-eGFP) gene(Diaconu et al., 2017). 
Retrovirus production. Sequences encoding J591, PSMA-HuVh, MSLN-scFv, MSLN-HuVh 
and MSLN- PSMA.HuVh were cloned into SFG backbone independently and sequenced for correctness. 
Retroviral supernatants were produced by transfection of 293T cells with the retroviral vectors, the 
RD114 envelope from RDF plasmid and the MoMLV gag-pol from PegPam3-e plasmid (Diaconu et al., 
2017). Supernatants were collected 48 hours and 72 hours after the transfection and filtered with 0.45µm 
filter.
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CAR-T cell generation. Buffy coats from healthy donors (Gulf Coast Regional Blood Center) 
were processed with Lymphoprep density separation (Fresenius Kabi Norge) to isolate peripheral blood 
mononuclear cells, which were then activated on plates coated with 1 µg/mL CD3 (Miltenyi Biotec) and 1 
µg/mL CD28 (BD Biosciences) mAbs. Two days later, activated T cells were transduced with retroviral 
supernatants on 24-well plates coated with retronectin with7 µg/mL (Takara Bio Inc.) , T cells were 
collected three days after transduction and expanded in 40% RPMI-1640(Gibco) and 40% Click’s 
medium (Irvine Scientific), 10% HyClone FBS (GE healthcare), 2 mM GlutaMAX(Gibco), 100 unit/mL 
of Penicillin and 100 mg/mL of streptomycin(Gibco) with 10 ng/mL IL-7(PeproTech) and 5 ng/mL IL-15 
(PeproTech). T cells were collected for functional assays 12-14 days after activation. 
Flow cytometry. mAbs for human CD3(APC-H7; SK7; 560176), CD4(BV711; SK3; 563028), 
CD8(APC; SK1; 340584), CD45RA (PE; HI100; 555489), CD45RO (BV786; UCHL1; 564290), CD69 
(FITC; L78; 347823), CCR7 (FITC; 150503; FAB197F-100), PD-1(PE-Cy7; EH12.1;561272), 
Lag3(PE;T47-530;565616), FLAG (APC; L5; 637308), Granzyme-B(PE;GB11;561142) from BD 
biosciences and BioLegend were used. Samples were acquired with BD FACSCanto II or BD 
LSRFortessa. A minimum of 10,000 events were acquired for each sample and were analyzed using 
FlowJo 10(FlowJo LLC). 
Western blot analysis. CAR-T cells were incubated with 2 µg anti-FLAG Ab in 100 µL PBS for 
20 mins on the ice and then with 2 µg goat anti-mouse secondary Ab for another 20 mins on the ice. Cells 
were then incubated in the 37°C water bath for the selected time points and then lysed with 2x Laemelli 
buffer for 10 mins. Cell lysates were then separated in 4% to 15% 10 well SDS-PAGE gels and 
transferred to polyvinylidene difluoride (PVDF) membranes at 75V for 120 mins (Bio-Rad). Blots were 
examined for human CD3ζ (Santa Cruz Biotechnology), p-Y142 CD3ζ (Abcam), pan-ERK (BD 
Biosciences), and pan-Akt, p-S473 Akt, and p-T202/Y204 MAPK (Cell Signaling Technology) with 
1:1000 dilution in 5% TBS-Tween milk. Membranes were incubated with HRP-conjugated secondary 
goat anti-mouse or goat anti-rabbit IgG (Santa Cruz) at a dilution of 1:3000 and imaged with the ECL 
substrate kit (Thermofisher) on the ChemiDoc MP System (Bio-Rad) according to the manufacturer's 
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instructions. 
Proliferation assay. T cells were labeled with 1.5 mM carboxyfluorescein diacetate succinimidyl 
ester (CFSE; Invitrogen) and plated with tumor cells at an E:T ratio of 1:1. CFSE signal dilution from 
gated T cells on day 5 was measured using flow cytometry(Diaconu et al., 2017). 
In vitro cytotoxicity assay. Tumor cells were seeded in 24-well plates at a concentration of 
0.5x105 cells/well overnight. CAR-T cells were added to the plate at an E:T ratio of 1:5 without 
exogenous cytokines. Cocultures were analyzed 5-7 days following coculture to measure residual tumor 
cells and T cells by flow cytometry. Dead cells were recognized by Zombie Aqua Dye (Biolegend) 
staining while CAR-T cells were identified by CD3 staining and tumor cells by GFP. 
Activation and exhaustion marker analysis. Tumor cells were seeded in 24-well plates at a 
concentration of 0.4x105 cells/well overnight. CAR-T cells were added to the plate at an E:T ratio of 1:2 
without exogenous cytokines. CD69, PD-1 and Lag3 expression were measured by flow cytometry from 
day 0 to day 5 each day after coculture. Dead cells were recognized by Zombie Aqua Dye (Biolegend) 
staining while CAR-T cells were identified by CD3 staining and tumor cells by GFP. For the granzyme-B 
staining, Golgi protein inhibitor (BD Biosciences) was added on day 1 of coculture for 6 hours. 
Cocultures were then first stained with Zombie Aqua Dye (Biolegend) and CD3 Ab followed by 
fixation/permeabilization solution (BD Biosciences). Intracellular staining of granzyme-B was then 
conducted. 
Cytokine analysis. 1 x 105 CAR-T cells were cocultured with 5x105 tumor cells in 24-well plates 
without exogenous cytokines. Supernatant after 24 hours was collected and cytokines (IFN-γ and IL-2) 
were measured with duplicates using ELISA kits (R&D system) following manufacturer’s instructions. 
Xenograft murine models. 6-8 weeks old female NSG mice were injected intravenously through 
tail vein with PC-3-PSMA-FFluc-eGFP of 1x106 per mice. Fourteen days later, CAR-T cells were 
injected intravenously through tail vein. For the high dosage PSMA.HuVh-CAR-T experiment, 4x106 
CAR-T cells per mice were injected while for the low dosage experiment, 1x106 CAR-T cells per mice 
were injected. Tumor growth was monitored by bioluminescence using IVIS-Kinetics Optical in vivo 
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imaging system (PerkinElmer). 
Statistical analysis. All data was calculated and represented as mean with standard deviation. 
One-way ANOVA with Turkey post hoc analysis was used to compare multiple groups. Two-tailed t test 
was used to compared two groups. A p value of less than 0.05 was significant. All calculations and 
figures were achieved by GraphPad Prism7 (La Jolla,CA). 
2.2 Result 
We constructed the J591.CAR and HuVh.CAR using the scFv from the PSMA-specific J591 Ab 
and the Vh from the PSMA-specific HuVh Ab, respectively joined to the CD8α stalk, CD28 
costimulatory domain and CD3ζ intracellular domain. A flag tag was incorporated into the cassettes to 
detect CAR expression by flow cytometry (Figure 1A). Activated T cells were successfully transduced 
and equally expressed the CARs (Figure 1B). Upon transduction, J591.CAR-T cells and HuVh.CAR-T 
cells showed similar expansion in vitro when exposed to IL-15 and IL-7 cytokines. CD19-specific CAR-T 
cells were used as control (Figure 1C). Furthermore, no differences were observed in T cell composition 
in CD19.CAR-T cells, J591.CAR-T cells and HuVh.CAR-T cells as assessed by flow cytometry at day 12 
– 14 of culture (Figure 1D).
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Figure 1  Conventional PSMA.CAR (J591) and heavy chain only PSMA.CAR (HuVh) are equally 
expressed by T cells. Schematic diagram of J591 and HuVh CAR constructs. (B) In vitro expansion of 
CD19.CAR-T cells, J591.CAR-T cells, HuVh.CAR-T cells and non-transduced (NT) T cells; error bars 
represent SD, (n = 4). (C) Representative flow cytometry plots illustrating CAR expression of the 
CD19.CAR-T cells, J591.CAR-T cells and HuVh.CAR-T cells. (D) Immunophenotypic composition of 
CD19.CAR-T cells, J591.CAR-T cells, HuVh.CAR-T cells and NT cells at day 14 of culture; error bars 
represent SD (n = 4). 
We then examined proximal signaling of J591.CAR-T cells and C5.CAR-T cells. As shown in 
Figure 2A, phosphorylation of the CAR-associated CD3ζ as well as the phosphorylation of Akt and ERK 
upon cross-linking of the CARs mediated by the anti-Flag Ab were equal in J591.CAR-T cells and 
HuVh.CAR-T cells. To examine the cytolytic activity of CAR-T cells upon antigen recognition, we 
measured granzyme-B degranulation through intracellular staining when CAR-T cells were cultured with 
tumor cells. J591.CAR-T cells and HuVh.CAR-T cells showed comparable secretion of granzyme-B 
10  
(Figure 2B). We also analyzed the kinetics of T cell activation upon CAR crosslinking by measuring 
CD69 expression. As shown in Figure 2C and 2D, equal upregulation and subsequent down regulation of 
CD69 was observed in J591.CAR-T cells and HuVh.CAR-T cells. Similarly, upregulation upon antigen 
stimulation and down regulation after antigen removal were observed for Lag-3 and PD-1 in both 
J591.CAR-T cells and C5.CAR-T cells (Figure 2D).
 
Figure 2 T cells expressing J591 or HuVh show comparable activities in vitro. Western blots 
detecting phosphorylation of CD3ζ, Akt and ERK of CAR-T cells activated via CAR crosslinking with 
anti- FLAG Ab followed by a secondary Ab to induce the aggregation of CARs. Total CAR.CD3ζ, and 
endogenous CD3ζ were used as loading controls. (B) Granzyme-B secretion of CD4+ and CD8+ T cells 
expressing either J591 or HuVh and cocultured overnight with PC3-PSMA-eGFP tumor cells at E:T 
ratio of 1:2; error bars represent SD (n = 4). (C) Representative flow plots illustrating the kinetics of 
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CD69 and Lag-3 expression of T cells expressing either J591 or HuVh. Blue light and red histograms 
illustrate isotype control and the specific marker, respectively. (D) Summary of CD69, PD-1 and Lag-3 
kinetic expression (n = 4). 
 To examine and compare the antitumor effect of HuVh.CAR-T cells with J591.CAR-T cells in 
vitro, we measured the remaining percentage of tumor cells left after 5 days of coculture with both CAR-
T cells. HuVh.CAR-T cells are able to specifically eliminate PSMA-positive target cells to the same 
extent as conventional scFv CAR-T cells and do not demonstrate off-target effect while CD19.CAR-T 
cells, as a control, did not kill the tumor cells (Figure 3A and 3B). We also measured cytokine secretion 
of IFN-γ and IL-2 after 24 hours of coculture. HuVh.CAR-T cells display a comparable release of IFN-γ 
and IL-2 compared with J591.CAR-T cells, which also confirms a comparable antitumor effect in vitro 
(Figure 3C). Further, we investigated proliferation of HuVh.CAR-T cells and J591.CAR-T cells through 
staining CAR T cells with CFSE and coculturing with tumor cells. Both J591.CAR-T cells and 
HuVh.CAR-T cells well proliferate upon encounter with tumor cells as shown by a broadened and 
reduced signal of CFSE (Figure 3D). Heavy-chain-only CAR-T cells therefore demonstrated in vitro 
toxicity against tumor cells to the same extent as conventional scFv CAR T cells. 
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Figure 3  T cells expressing J591 or HuVh show similar antitumor activities in vitro. Representative 
flow cytometry plots showing coculture with C4-2-eGFP (positive control), PC-3-eGFP (negative 
control) and PC-3-PSMA-eGFP (target cell). CD19.CAR-T cells, J591.CAR-T cells and HuVh.CAR-T 
cells were cocultured with C4-2-eGFP, PC-3-eGFP and PC-3-PSMA-eGFP cell lines at an E:T ratio of 
1:5 for 6 days(B) Summary of coculture of CD19.CAR-T cells, J591.CAR-T cells and HuVh.CAR-T 
cells with C4-2-eGFP, PC-3-eGFP and PC-3-PSMA-eGFP cell lines; error bars represent SD(n=4). (C) 
IFN-γ and IL-2 release from the coculture supernatant with CD19.CAR-T cells, J591.CAR-T cells and 
HuVh.CAR- T cells as measured by ELISA (n=4). (D) Representative flow cytometry figures showing 
CFSE proliferation assay. Blue and gray histograms represent activated and control groups 
respectively(n=4). 
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 Next, an in vivo model is used to investigate the antitumor effect of PSMA-HuVh.CAR-T cells in 
vivo. a high dosage group and a low dosage group experiments are independently conducted in NSG mice 
by inoculation of PSMA-positive tumor model and transfusion of CAR-T cells (Figure 4A). Both high 
dosage group and low dosage group showed a complete tumor eradication as measured by tumor 
bioluminescence (Figure 4B and 4C). The high dosage group stopped weekly imaging on day 60 due to 
the graft-versus-host disease (GVHD) and the experiment was suspended. The low dosage group however 
did not show significant GVHD. Heavy-chain-only CAR-T cells therefore demonstrated comparable 
antitumor effect compared with scFv-based CAR-T cells in vivo. 
 
Figure 4 T cells expressing J591 or HuVh show comparable antitumor activities in vivo Schematic 
schedule of metastatic prostate cancer model using PC-3-PSMA-FFluc-eGFP tumor cells in NSG mice 
with either a high or low dosage of CAR-T cells. (B) Representative images of tumor bioluminescence at 
selected time points post T cell injections for high dosage(left) and low dosage(right) groups. (C) 
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Kinetics of tumor growth in (B) measured by bioluminescence with 5 mice per group for high dosage 
(left) and low dosage (right) groups. 
 Next, we move onto another target MSLN and construct the conventional scFv CAR-T cells and 
HuVh.CAR-T cells respectively in the same backbone as J591.CAR-T cell.  In a similar fashion, we 
examined the in vitro cytotoxicity of HuVh.CAR-T cell through tumor coculture, cytokine release assay 
and proliferation assay. As shown in Figure 5A and Figure 5B, both CAR T cells selectively lead to 
complete elimination of MSLN-positive tumor cells without off-target response. They well proliferate 
upon antigen recognition and have a similar cytokine release profile, demonstrating a comparable in vitro 
cytotoxicity with scFv CAR-T cell (Figure 5C and 5D). 
 
Figure 5 T cells expressing MSLN.scFv or HuVh show comparable antitumor activities in vitro 
Representative flow cytometry plots showing coculture with PC-3-eGFP (negative control) and Aspc-1-
eGFP (target cell). CD19.CAR-T cells, MSLN.scFv.CAR-T cells and MSLN.HuVh.CAR-T cells were 
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cocultured with PC-3-eGFP and Aspc-1-eGFP cell lines at an E:T ratio of 1:5 for 6 days. (B) Summary of 
coculture of CD19.CAR-T cells, MSLN.scFv.CAR-T cells and MSLN.HuVh.CAR-T cells with PC-3-
eGFP and Aspc-1- eGFP cell lines; error bars represent SD (n=4). (C) IFN-γ and IL-2 release from the 
coculture supernatant with CD19.CAR-T cells, MSLN.scFv.CAR-T cells and MSLN.HuVh.CAR-T cells 
as measured by ELISA(n=4). (D) Representative flow cytometry figures illustrating CFSE proliferation 
assay. Blue and gray histograms represent activated and control groups respectively(n=4). 
2.3 Discussion 
 The extracellular part of the CARs that is responsible for antigen engagement is not simply 
limited to scFv. The signaling pathway is activated when the extracellular region recognizes the surface 
antigen and leads to CAR molecule clustering, which in turn starts the intracellular phosphorylation and 
signal transduction cascade. scFv-based CARs also face concerns. Transforming a full antibody into a 
scFv form may not necessarily keep the same affinity and avidity. scFvs are also prone to self-aggregation 
in the absence of the antigen, instability and dimerization, which may lead to loss of function of CARs in 
vivo(Murad et al., 2018). Therefore, exploring alternatives of scFv-based CAR is desirable to improve 
CAR-T cell therapy. Many groups have invented CARs that do not rely on scFv to achieve tumor 
targeting. Natural receptor-based CARs such as NKG2D CAR, which retains the complete extracellular 
domain of the NK receptor, has been showed to effectively eliminate lymphoma and many solid 
tumors(Barber et al., 2011; Barber et al., 2008; Zhang et al., 2005). Another category of non-scFv CAR 
involve the uses of ligands to cytokine receptors. IL-13Rα2 has been targeted to treat glioblastoma, where 
IL-13Rα2 is overexpressed, and IL-13Rα2 CAR T cells are able to completely remove established tumors 
in vivo(Kong et al., 2012). In this work, a heavy-chain-only CAR was constructed and was shown to be as 
effective as conventional scFv CAR-T cells in antitumor response. The heavy-chain-only CAR was 
consistently expressed in T cells and showed comparable growth and immunophenotypes as canonical 
scFv CAR-T cells (Figure 1). The heavy-chain-only CAR-T cells demonstrated similar signaling 
pathways upon cross-linking (Figure 2A) and was activated and exhausted in a comparable fashion 
compared with scFv CAR-T cells (Figure 2D). The heavy-chain-only CAR-T cells also exhibited 
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comparable cytotoxicity, cytokine release and proliferation upon engagement with tumor cell in vitro 
(Figure 2B, Figure3 and Figure 5). Lastly, the heavy-chain-only CAR-T cells eradicated tumor cells in 
vivo in the same extent as scFv CAR- T cells (Figure 4). Granted, finding the heavy chain that binds as 
strongly as scFv to the surface antigen might not be applicable for every tumor cell line. Nonetheless, in 
this work two targets, PSMA and MSLN, are fortunate to have heavy chain that elicits uncompromised 
binding. With only a heavy chain, retroviral vector of CAR therefore can be further developed to improve 
CAR-T cell efficiency and safety. For example, to solve the issue of tumor antigen heterogeneity in solid 
tumors, a double-heavy-chain CAR construct, namely two heavy chains connected by a linker, can be 
developed to achieve dual targeting. Inhibitory pathways inside the immunosuppressive TMEs can be 
overcome by adding autocrine pathways (Chen et al., 2019; Li et al., 2017; Pegram et al., 2012). For the 
safety aspect, CRS can be solved by adding suicide genes (Diaconu et al., 2017) or surface markers that 
allow complement or antibody-dependent cellular cytotoxicity upon administration of mAb (Paszkiewicz 
et al., 2016; Philip et al., 2014). In summary, this heavy-chain-only CAR-T cell could lay the foundation 
for future development of CAR-T cell therapy to enhance antitumor response in solid tumors where T cell 
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